GlassScriptPhysician profile
Irene Halmari
NPI 1851795074
$1,297.59
in general payments reported to CMS, 2019-2025
20 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $541 · 2023: $284 · 2024: $143 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $292.88 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Glaxosmithkline, LLC. | $236.72 | 2022-2023 | Trelegy Ellipta |
| Abbvie INC. | $143.04 | 2022-2025 | |
| Novo Nordisk INC | $139.84 | 2022-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $102.14 | 2022-2023 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $41.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.90 | 2025 | Ajovy |
| Pfizer INC. | $32.73 | 2023-2025 | |
| Csl Behring | $32.11 | 2025 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.30 | 2022-2023 | Synjardy, Jardiance |
| Amgen INC. | $27.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.16 | 2022 | |
| Impel Pharmaceuticals LLC | $23.41 | 2025 | Trudhesa |
| Sequel Med Tech, LLC | $23.10 | 2025 | Twiist |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $20.31 | 2025 | Vyvgart Hytrulo |
| Daiichi Sankyo INC. | $18.17 | 2022 | |
| Vanda Pharmaceuticals INC. | $16.77 | 2023 | Hetlioz |
| Idorsia Pharmaceuticals US INC | $12.99 | 2023 | Quviviq |
| Shield Therapeutics INC | $12.97 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Halmari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.